After a slow 2024, the biotech shell company Concentra Biosciences is back, offering to buy four biotechs in the past month ...

Discover why some biotechs fail but survive with cash on hand, and how players like Concentra are trying to unlock trapped ...

Concentra is living up to its reputation of buying battered biotechs, swooping in to grab iTeos after the failure of its GSK-partnered TIGIT drug.

WATERTOWN, Mass. and GOSSELIES, Belgium - iTeos Therapeutics, Inc. (NASDAQ: ITOS), a biopharmaceutical company with a market capitalization of $265 million, and its partner GSK have decided to ...

iTeos ends belrestotug program with GSK after Phase 2 trial fails to meet key survival goals; company explores strategic options to boost shareholder value.

A two-drug regimen involving an experimental cancer immunotherapy from iTeos Therapeutics and GSK didn’t significantly delay tumor progression in a Phase 2 trial, leading the companies to end ...

WATERTOWN, Mass. and GOSSELIES, Belgium - iTeos Therapeutics, Inc. (NASDAQ: ITOS), a biopharmaceutical company with a market capitalization of $265 million, and its partner GSK have decided to ...

LONDON - GSK plc (LSE/NYSE:GSK), in collaboration with iTeos Therapeutics, Inc., announced today the termination of their joint development program for belrestotug, an investigational anti-TIGIT ...

TIGITs took another tumble with GSK plc’s decision to end a development program and a collaboration with Iteos Therapeutics Inc. New top-line results from a phase II study in non-small-cell lung ...

iTeos Therapeutics, Inc. (NASDAQ:ITOS) reported topline results from an updated interim analysis of the GALAXIES Lung-201 Phase 2 study on Tuesday. The trial sponsored by GSK Plc (NYSE:GSK ...